Unexpected CD4 decay and hidden adherence gaps

Published: 17 May 2023| Version 1 | DOI: 10.17632/3424c9c6k6.1
Amedeo Capetti


Dataset of hidden non adherent patients related to paper "Unexpected CD4 decay, hidden adherence gaps, resilience and the need for long-acting therapy in a single HIV outpatients’ cohort" This study examines hidden non-adherence to antiretroviral therapy in a setting of persistent optimal viral suppression but concordant absolute and percent CD4 decay by >10% from the previous test. Investigated, 25% admitted very long treatment interruptions, compensated by treatment resumption before the subsequent testing. Of 668 HIV-infected subjects, 61 fulfilled the pre-specified criteria for significant CD4 decay and 15 (2.25%) admitted treatment interruptions. Eleven treatment interruptions exceeded 28 days, and none was shorter than 15 days. CD4 recovery was worse at 6 months in non-adherent subjects (-0.5 vs + 16/mmc, p<0.0001) and in non adherence vs immune decay time-related with COVID-19 (0 vs + 22/mmc, p<0.0001). Reasons for interrupting treatment were travel, psychological, poverty-related, addiction and love problems. Long-acting regimens, with stringent control of precision in timely administration, may protect PLWH from damaging their health status and possibly transmit HIV.


Steps to reproduce

Data were collected form the patients' eCRF


HIV Therapy, Treatment Adherence in Long-Term Care